放疗及合并化疗治疗Ⅲ期肺腺癌疗效分析

Evaluation of radiotherapy plus chemotherapy in the treatment of patients with stace Ⅲ adenocarcinoma of lung

摘要: 1989年元月至1992年12月间52例经组织学或细胞学证实的Ⅲ期肺腺癌，其中24例单用放疗，28例放疗加化疗（CEP6例，PMF10例，卫康醇+DDP12例）。单放组CR+PR33.3%，放十化组CR+PR53.6%，两组近期疗效无显著差异（P>0.1），放十化组发生胃肠副反应及白细胞减少率明显高于单放组（P<0.05），但患者均能耐受。单放组远处转移率虽高于放十化组（33%：18%），但未显示统计学差异（P>0.1）。本结果表明放十化治疗Ⅲ期肺腺癌并未明显提高近期疗效，故对Ⅲ期肺腺癌的治疗方案尚有待进一步研究。

Abstract: Between 1989 and 1992, 52 patients with stage Ⅲ adenocarcinoma of lung were treated, of them, 24_underwent radiotherapy only and 28 were treated by radiotherapy plus chemotherapy. The response rate (CR+PR) were 33.35 and 53.6% respectively (P>0.1). In patients with chemotherapy, the incidence of side effects (vomiting, nausea, Ieucopenia and thrombocytopenia) was significantly higher than those without chemotherapy (P<0.05). but no discontinuation of the treatment happened because of side effects. In patients without chemotherapy, the systemic metastase rate was higher than patients with chemotherapy (33%:18%). but no statistical differance was found. It was suggested that radiotherapy plus chemotherapy in the treatment of patients with stage Ⅲ adenocarcinoma of lung did not show better result.